Skip to content

Research for miRNAs as prognosis biomarkers of renal cell carcinoma

Research for miRNAs as prognosis biomarkers of renal cell carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018904
Enrollment
Unknown
Registered
2018-10-16
Start date
2018-11-01
Completion date
Unknown
Last updated
2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

Gold Standard:Clinical outcome

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosed as renal cell carcinoma by imaging (CT or MRI)or aspiration biopsy; 2. Informed consent have been signed by patients or their family; 3. With complete follow-up for 5 years; 4. With complete paraffin specimen.

Exclusion criteria

Exclusion criteria: 1. Preoperative consideration is likely to be primary renal clear cell carcinoma, but postoperative pathological diagnosis excludes renal cancer or is not primary renal cancer; 2. Patients with other malignant tumors; 3. Patients with other severe liver and kidney dysfunction, diabetes, severe infection, and cardiac insufficiency.

Design outcomes

Primary

MeasureTime frame
microRNA;

Countries

China

Contacts

Public ContactYongqing Lai

Peking University Shenzhen Hospital

yqlord@outlook.com+86 13500058425

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026